Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Acta Oncol ; 50(8): 1158-66, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22023115

RESUMEN

BACKGROUND: Securin is an oncogene with functions in cell proliferation, tumour initiation and progression. Its prognostic value in rectal cancer is somewhat unknown. Accordingly, we studied securin expression together with Ki-67 in rectal cancer in relation to preoperative (chemo)radiotherapy (RT) and disease outcome. MATERIAL AND METHODS: Biopsies (n = 65 for securin; n = 57 for Ki-67) and operative specimens (n = 207) from 211 patients treated with short-course RT (n = 87), long-course RT (n = 54) or surgery only (n = 70) were studied with immunohistochemistry (IHC) for securin and Ki-67 expression. In the long-course RT group, 45 patients received chemotherapy (5-fluorouracil or capecitabine) concomitantly with RT. The results of IHC were related to clinicopathological variables, disease outcome and tumour regression grade (TRG) after long-course RT. RESULTS: Both markers showed significant reduction after RT (p < 0.001). No differences in expression was seen in the long-course RT group between the patients with or without concomitant chemotherapy (p = 0.23 for securin; p = 0.31 for Ki-67). Low Ki-67 expression, but not that of securin, in operative specimens was significantly related to excellent TRG (p = 0.02 for Ki-67; p = 0.21 for securin). In univariate survival analysis, excellent TRG predicted longer disease-specific survival (DSS; p = 0.03). In multivariate Cox analysis, high securin expression after long-course (chemo)RT was an independent predictor of shorter DSS (p = 0.036) together with patient age (p = 0.043) and disease recurrence (local or distant; p = 0.009), whereas no similar appearance was seen in other treatment groups. CONCLUSION: Securin expression in rectal cancer is significantly reduced after RT. High securin expression and poor TRG after long-course (chemo)RT are indicators of unfavourable disease outcome.


Asunto(s)
Desoxicitidina/análogos & derivados , Fluorouracilo/análogos & derivados , Fluorouracilo/uso terapéutico , Proteínas de Neoplasias/biosíntesis , Neoplasias del Recto/metabolismo , Neoplasias del Recto/terapia , Anciano , Antimetabolitos Antineoplásicos/uso terapéutico , Biopsia , Capecitabina , Quimioterapia Adyuvante , Desoxicitidina/uso terapéutico , Supervivencia sin Enfermedad , Femenino , Humanos , Inmunohistoquímica , Antígeno Ki-67/biosíntesis , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Modelos de Riesgos Proporcionales , Dosificación Radioterapéutica , Radioterapia Adyuvante , Neoplasias del Recto/patología , Securina , Resultado del Tratamiento
2.
J Histochem Cytochem ; 63(9): 710-20, 2015 09.
Artículo en Inglés | MEDLINE | ID: mdl-26001829

RESUMEN

Decorin is generally recognized as a tumor suppressing molecule. Nevertheless, although decorin has been shown to be differentially expressed in malignant tissues, it has often remained unclear whether, in addition to non-malignant stromal cells, cancer cells also express it. Here, we first used two publicly available databases to analyze the current information about decorin expression and immunoreactivity in normal and malignant human colorectal tissue samples. The analyses demonstrated that decorin expression and immunoreactivity may vary in cancer cells of human colorectal tissues. Therefore, we next examined decorin expression in normal, premalignant and malignant human colorectal tissues in more detail using both in situ hybridization and immunohistochemistry for decorin. Our results invariably demonstrate that malignant cells within human colorectal cancer tissues are devoid of both decorin mRNA and immunoreactivity. Identical results were obtained for cells of neuroendocrine tumors of human colon. Using RT-qPCR, we showed that human colon cancer cell lines are also decorin negative, in accordance with the above in vivo results. Finally, we demonstrate that decorin transduction of human colon cancer cell lines causes a significant reduction in their colony forming capability. Thus, strategies to develop decorin-based adjuvant therapies for human colorectal malignancies are highly rational.


Asunto(s)
Neoplasias Colorrectales/metabolismo , Neoplasias Colorrectales/patología , Decorina/metabolismo , Carcinogénesis , Carcinoma/genética , Carcinoma/metabolismo , Carcinoma/patología , Línea Celular Tumoral , Colon/citología , Colon/patología , Neoplasias Colorrectales/genética , Metilación de ADN , Bases de Datos de Proteínas , Decorina/genética , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Hibridación in Situ , Tumores Neuroendocrinos/genética , Tumores Neuroendocrinos/metabolismo , Tumores Neuroendocrinos/patología , Regiones Promotoras Genéticas/genética , Transporte de Proteínas , ARN Mensajero/genética , ARN Mensajero/metabolismo
3.
Hum Pathol ; 44(6): 966-74, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23332924

RESUMEN

The cancer stem cell marker aldehyde dehydrogenase 1 (ALDH1) associates with treatment resistance and adverse outcome in several human cancers. We studied ALDH1 expression in rectal cancer, with special emphasis on its association with treatment response and disease outcome. Immunohistochemical staining for ALDH1 was conducted for 64 biopsies and 209 operative samples from rectal cancer patients treated with short- (n = 89) or long-course (n = 46) (chemo)radiotherapy plus surgery, or with surgery only (n = 74). The staining results were compared to clinicopathological variables, tumor regression grade (TRG) and disease outcome. Nuclear ß-catenin expression pattern was analyzed from 197 operative samples. Positive ALDH1 expression was present in 149 operative samples (71%), correlating with deficient nuclear ß-catenin regulation (P = .018). In a pairwise comparison of respective biopsy and operative samples, ALDH1 expression remained stable or increased after preoperative (chemo)radiotherapy in most of the cases, while it decreased in few cases only (P = .02 for positive/negative category; P <.001 for intensity). ALDH1 expression did not, however, relate to tumor regression grade. In node-negative rectal cancer, ALDH1 expression was an independent predictor of short disease-free and disease-specific survival (P = .044; P = .049), specifically among patients treated with adjuvant chemotherapy. We conclude that ALDH1 associates with deregulated ß-catenin signaling, supporting the role of ALDH1 in rectal cancer stemness. ALDH1 expression relates to poor outcome in early stage rectal cancer, a group where new prognostic tools are particularly needed, and may indicate chemo- and radioresistance.


Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma/metabolismo , Isoenzimas/biosíntesis , Neoplasias del Recto/metabolismo , Retinal-Deshidrogenasa/biosíntesis , Anciano , Familia de Aldehído Deshidrogenasa 1 , Carcinoma/patología , Carcinoma/terapia , Quimioradioterapia , Procedimientos Quirúrgicos del Sistema Digestivo , Supervivencia sin Enfermedad , Resistencia a Antineoplásicos , Femenino , Humanos , Inmunohistoquímica , Isoenzimas/análisis , Estimación de Kaplan-Meier , Masculino , Estadificación de Neoplasias , Modelos de Riesgos Proporcionales , Neoplasias del Recto/patología , Neoplasias del Recto/terapia , Retinal-Deshidrogenasa/análisis , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA